» Articles » PMID: 34223058

Clinical Characteristics and Treatment Outcomes of Patients with MDR Tuberculosis in Dar Es Salaam Region, Tanzania

Overview
Date 2021 Jul 5
PMID 34223058
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In Tanzania more than 28% of all multi-drug resistant tuberculosis (MDR-TB) cases occur in Dar es Salaam. However, information about management and clinical outcomes of patients with MDR-TB in the region is scarce, and hence the need for this study.

Methods: A 5-year retrospective cohort study was conducted in six centres in Dar es Salaam. Descriptive statistics were used to summarize social demographics and clinical characteristics. Associations between occurrence of adverse events, regimen change and cure were determined using the Chi-square test whereas factors associated with mortality were determined using the Log-ranking test and Cox regression model.

Results: Three-hundred patient files were found and reviewed. The majority were male 199 (66.3%), aged 25-44 years [176 (58.7%)] and 89 (30.1%) were HIV co-infected. 186 (62%) completed their treatment, 68 (22.0%) were on treatment and 9 (3.3%) were lost to follow-up. The majority, 152 (51.0%) were managed using long MDR-TB regimens. The overall mortality rate was 5.7 per 1000 MDR-TB patients. A higher mortality rate was associated with being ≥45 years [adjusted hazard ratio (AHR): 10.82, 95% CI: 1.14-102.74, 0.038), female (AHR: 5.92, 95% CI: 1.75-20.08, 0.004), on a short anti-TB regimen (AHR: 4.34, 95% CI: 1.41-13.35, 0.010), HIV co-infected [crude hazard ratio (CHR): 2.56, 95% CI: 1.01-6.50, 0.048), on concomitant long-term medication use (CHR: 2.99, 95% CI: 1.17-7.64, 0.022) and having other co-morbidities (CHR: 3.45, 95% CI: 1.32-9.02, 0.011).

Conclusions: MDR-TB mortality was associated with short anti-TB regimens, sex, age, concomitant long-term medication use and HIV coinfection. In this population, use of long and individualized regimens is recommended.

Citing Articles

Patients' acceptability, adherence and satisfaction on the modified shorter all-oral multidrug-resistant tuberculosis regimen: a two-phase cross-sectional study in Tanzania.

Lalashowi J, Mvungi H, Mwaisango Z, Pamba D, Mohamed A, Gitige C BMJ Open. 2025; 15(3):e088556.

PMID: 40037680 PMC: 11881200. DOI: 10.1136/bmjopen-2024-088556.


Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis.

Abraham Y, Assefa D, Hailemariam T, Gebrie D, Debela D, Geleta S BMC Infect Dis. 2024; 24(1):1087.

PMID: 39354416 PMC: 11443784. DOI: 10.1186/s12879-024-09960-3.


Community-based directly observed therapy is effective and results in better treatment outcomes for patients with multi-drug resistant tuberculosis in Uganda.

Makabayi-Mugabe R, Musaazi J, Zawedde-Muyanja S, Kizito E, Fatta K, Namwanje-Kaweesi H BMC Health Serv Res. 2023; 23(1):1248.

PMID: 37957610 PMC: 10644403. DOI: 10.1186/s12913-023-10120-7.


Treatment outcomes of multi-drug resistant tuberculosis patients with or without human immunodeficiency virus co-infection in Africa and Asia: Systematic review and meta-analysis.

Kajogoo V, Lalashowi J, Olomi W, Atim M, Assefa D, Sabi I Ann Med Surg (Lond). 2022; 78:103753.

PMID: 35600168 PMC: 9121254. DOI: 10.1016/j.amsu.2022.103753.

References
1.
Mollel E, Lekule I, Lynen L, Decroo T . Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study. Int Health. 2019; 11(6):520-527. DOI: 10.1093/inthealth/ihz005. View

2.
Chingonzoh R, Manesen M, Madlavu M, Sopiseka N, Nokwe M, Emwerem M . Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting database in the Eastern Cape Province, South Africa, 2011 to 2013. PLoS One. 2018; 13(8):e0202469. PMC: 6104983. DOI: 10.1371/journal.pone.0202469. View

3.
Zignol M, Hosseini M, Wright A, Weezenbeek C, Nunn P, Watt C . Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006; 194(4):479-85. DOI: 10.1086/505877. View

4.
Chem E, Van Hout M, Hope V . Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis. BMC Infect Dis. 2019; 19(1):723. PMC: 6697933. DOI: 10.1186/s12879-019-4317-4. View

5.
Baxter R, HASTINGS N, Law A, Glass E . A rapid and robust sequence-based genotyping method for BoLA-DRB3 alleles in large numbers of heterozygous cattle. Anim Genet. 2008; 39(5):561-3. DOI: 10.1111/j.1365-2052.2008.01757.x. View